Tetra Bio Pharma Inc Stock Analysis:
STA Research Initiates Tetra Bio Pharma Inc. with a Speculative Buy rating and a target price of $0.20 on the company’s stock.
Based on the Tetra Bio Pharma Inc stock forecasts from 1 analysts, the average analyst target price for Tetra Bio Pharma Inc is $0.20 over the next 12 months. Tetra Bio Pharma Inc’s average analyst rating is Speculative Buy. Stock Target Advisor’s own stock analysis of Tetra Bio Pharma Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Tetra Bio Pharma Inc’s stock price was CAD 0.04. Tetra Bio Pharma Inc’s stock price has changed by -12.50% over the past week, -41.67% over the past month and -85.71% over the last year.
About Tetra Bio Pharma Inc (TBP:CA:TSX)
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada
What we like:
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What we don’t like:
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector.